

RECEIVED
CENTRAL FAX CENTER

FEB 28 2007

Amendments to the Claims:

The present listing of the claims replaces all past listings of the claims:

Listing of claims:

1. (Canceled)

2. (Currently Amended) Pharmaceutical preparation pursuant to claim 3, comprising at least one antiphlogistic-antibiotic salt of gentamicin-ibuprofen, gentamicin-naproxen, gentamicin-indomethacin, gentamicin-dexamethasone-21-phosphate, gentamicin-triamcinolone-21-phosphate, tetracycline-indomethacin, tetracycline-indomethacin, neomycin-indomethacin, clindamycin-indomethacin, streptomycin-naproxen, tetracycline-naproxen, clindamycin-naproxen, or streptomycin-ibuprofen.

3. (Currently Amended) Pharmaceutical preparation, comprising at least one antiphlogistic-antibiotic salt whose cationic component contains at least one representative from the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxycycline, oxytetracycline and rolitetracycline and whose anionic component contains at least one representative from the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate, which pharmaceutical preparation is in the form of at least one member selected from the group consisting of molded bodies, tablets, powders, granules, fibers, knitted fabrics and fleece.

4. (Currently Amended) Pharmaceutical preparation, comprising at least one antiphlogistic-antibiotic salt whose cationic component contains at least one representative from the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxycycline, oxytetracycline and rolitetracycline and whose anionic component contains at least one representative from the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate, which pharmaceutical preparation is part of a coating applied onto at least one member selected from the group consisting of molded bodies, powders, granules, fibers, knitted fabrics and fleece.

5. (Previously Presented) Pharmaceutical preparation, comprising a mixture in a solid state of aggregation, which mixture is composed of at least one easily water soluble salt of at least one of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxycycline, oxytetracycline and/or rolitetracycline and at least one easily water soluble salt of at least one of ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate and at least one inorganic and/or organic pharmaceutical adjuvant, and said pharmaceutical preparation has a shape of tablets and/or molded bodies.

6. (Currently Amended) Method for producing a pharmaceutical preparation pursuant to claim 3, comprising the following steps:

a) mixing an easily water soluble salt of at least one of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxycycline, oxytetracycline and/or rolitetracycline with at least one easily water soluble salt of at least one of ibuprofen, naproxen,

indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate, and forming the at least one antiphlogistic-antibiotic salt by reciprocal salt exchange; and

b) forming the pharmaceutical preparation into the form of at least one member selected from the group consisting of molded bodies, tablets, powders, granules, fibers, knitted fabrics and fleece forming hardly water soluble antiphlogistic antibiotics salts, wherein said salts form controlled release antiphlogistic/antiphlogistics antibiotic/antibiotics drugs.

7. (Currently Amended) Method for producing a pharmaceutical preparation pursuant to claim 5, comprising the following steps:

a) mixing the at least one easily water soluble salt of at least one of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxycycline, oxytetracycline and/or rolitetracycline with the at least one easily water soluble salt of at least one of ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate and the at least one inorganic and/or organic pharmaceutical adjuvant; and

b) forming the pharmaceutical preparation into the shape of tablets and/or molded bodies forming hardly water soluble antiphlogistic antibiotics salts, wherein said salts form controlled release antiphlogistic/antiphlogistics antibiotic/antibiotics drugs.

8. (Previously Presented) A method of treating a bacterial infection in a patient comprising administering a pharmaceutical preparation pursuant to claim 3 to said patient as a controlled-release antibiotics drug.

9. (Currently Amended) A permanent or temporary implant comprising a pharmaceutical preparation, comprising at least one antiphlogistic-antibiotic salt whose cationic component contains at least one representative from the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxycycline, oxytetracycline and rolitetracycline and whose anionic component contains at least one representative from the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate, which pharmaceutical preparation is in the form of at least one member selected from the group consisting of molded bodies, tablets, powders, granules, fibers, knitted fabrics and fleece.

10. (Previously Presented) A permanent or temporary implant comprising a pharmaceutical preparation, comprising a mixture in a solid state of aggregation, which mixture is composed of at least one easily water soluble salt of at least one of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxycycline, oxytetracycline and/or rolitetracycline and at least one easily water soluble salt of at least one of ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate and at least one inorganic and/or organic pharmaceutical adjuvant, and said pharmaceutical preparation has a shape of tablets and/or molded bodies.

11. (Currently Amended) A method for producing a pharmaceutical preparation according to claim 6, wherein said ~~hardly water soluble antiphlogistic antibiotics salts are in pharmaceutical preparation is formed into~~ tablet and/or molded body form.

12. (Currently Amended) A method for producing a pharmaceutical preparation according to claim 7, wherein said ~~hardly water soluble antiphlogistic antibiotics salts are in pharmaceutical preparation is formed into~~ tablet and/or molded body form.

13. (Currently Amended) The method according to claim 6, wherein said forming the at least one antiphlogistic-antibiotic salt by reciprocal salt exchange comprises precipitating the antiphlogistic-antibiotic salt-antibiotics salts.

14. (Currently Amended) The method according to claim 7, wherein said forming which further comprises precipitating antiphlogistic-antibiotics salts by introducing the tablets and/or molded bodies into water.

15. (Currently Amended) Pharmaceutical preparation pursuant to claim 4, comprising at least one antiphlogistic-antibiotic salt of gentamicin-ibuprofen, gentamicin-naproxen, gentamicin-indomethacin, gentamicin-dexamethasone-21-phosphate, gentamicin-triamcinolone-21-phosphate, tetracycline-indomethacin, tetracycline-indomethacin, neomycin-indomethacin, clindamycin-indomethacin, streptomycin-naproxen, tetracycline-naproxen, clindamycin-naproxen, or streptomycin-ibuprofen.

16. (Previously Presented) Pharmaceutical preparation pursuant to claim 5, comprising at least one salt of gentamicin-ibuprofen, gentamicin-naproxen, gentamicin-indomethacin, gentamicin-dexamethasone-21-phosphate, gentamicin-triamcinolone-21-phosphate, tetracycline-indomethacin, tetracycline-indomethacin, neomycin-indomethacin, clindamycin-indomethacin, streptomycin-naproxen, tetracycline-naproxen, clindamycin-naproxen, or streptomycin-ibuprofen.

17. (Currently Amended) Pharmaceutical preparation pursuant to claim 9, comprising at least one antiphlogistic-antibiotic salt of gentamicin-ibuprofen, gentamicin-naproxen, gentamicin-indomethacin, gentamicin-dexamethasone-21-phosphate, gentamicin-triamcinolone-21-phosphate, tetracycline-indomethacin, tetracycline-indomethacin, neomycin-indomethacin, clindamycin-indomethacin, streptomycin-naproxen, tetracycline-naproxen, clindamycin-naproxen, or streptomycin-ibuprofen.

18. (Currently Amended) Pharmaceutical preparation The implant pursuant to claim 10, comprising wherein the pharmaceutical preparation comprises at least one salt of gentamicin-ibuprofen, gentamicin-naproxen, gentamicin-indomethacin, gentamicin-dexamethasone-21-phosphate, gentamicin-triamcinolone-21-phosphate, tetracycline-indomethacin, tetracycline-indomethacin, neomycin-indomethacin, clindamycin-indomethacin, streptomycin-naproxen, tetracycline-naproxen, clindamycin-naproxen, or streptomycin-ibuprofen.

RECEIVED
CENTRAL FAX CENTER

FEB 28 2007

CONDITIONAL PETITION FOR EXTENSION OF TIME

If entry and consideration of the amendments above requires an extension of time, Applicants respectfully requests that this be considered a petition therefor. The Commissioner is authorized to charge any fee(s) due in this connection to Deposit Account No. 14-1263.

ADDITIONAL FEE

Please charge any insufficiency of fees, or credit any excess, to Deposit Account No. 14-1263.

USSN 10/600,556
Amendment Under 35 CFR §1.116 filed February 28, 2007

Page 8